Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
709 (USA) · Dr. Novak
consented 2012-07-31
AEs
4
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Mild APPLICATION SITE DERMATITIS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-08-16 (study day 17.0); relationship: PROBABLE
mild
assessed
Mild APPLICATION SITE DERMATITIS — outcome: RECOVERED/RESOLVED; onset 2012-08-16 (study day 17.0); relationship: PROBABLE
severe
assessed
Severe APPLICATION SITE DERMATITIS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-08-21 (study day 22.0); relationship: PROBABLE
mild
assessed
Mild DIARRHOEA — outcome: RECOVERED/RESOLVED; onset 2012-08-30 (study day 31.0); relationship: POSSIBLE
Data queries
No data queries.